BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its ...
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to raise ...
BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating ...
A research team has developed a new RNA-based system that can detect coronavirus infection in real time inside living cells—and even trigger antiviral responses only when infection occurs.
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...
TransCode Therapeutics RNAZ reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback